November 18, 2021
ADAPTTECH PARTNERS WITH MODUS HEALTH TO EXPAND PRODUCT PORTFOLIO
Adapttech licenses IP to industry-leading mobility tracking software to improve patient mobility outcomes.
BIRMINGHAM, UK and PORTO, PORTUGAL – Biomedical scale-up Adapttech, today announced that it has licensed IP from leading activity-monitoring company, Modus Health. Adapttech will now integrate and adapt Modus’ StepWatch™ software, the gold standard for accurate motion monitoring, into its future product designs and patient outcome models.
Modus technology has been validated in over 500 peer-reviewed publications, with StepWatch being used as the gold standard by researchers and companies such as Google, Fitbit, and Samsung Digital Health for measuring the accuracy of their fitness monitors.
Adapttech promotes patient mobility by creating devices that leverage key health data points to deliver improved patient outcomes. Adapttech’s first product, the INSIGHT System, is designed to improve the fitting process of lower-limb prostheses for amputees; this new deal will see the company expand its market focus in patient outcomes management through new hardware devices, apps, data servers, AI-supported analysis, and professional reporting for insurance payers and healthcare professionals.
Frederico Carpinteiro, CEO, Adapttech, said: “Our partnership with Modus Health supports the development of new solutions based on their industry leading technology and our market reach, this will enable Adapttech to better help our clinical customers improve the mobility of their patients. We have an exciting pipeline of products in development which are undergoing user-testing ahead of being released next year – our first product will showcase the successful incorporation of StepWatch technology.”
StepWatch™ is an FDA-listed medical device which accurately measures more than 20 key points of information in the wearer’s walking pattern, including cadence, daily steps, walking duration, and more. This data can be used to assess patient conditions, even beyond mobility, and support prescribed solutions.
Teri Chou, CEO, Modus Health, said: “StepWatch technology has been featured in multiple peer-reviewed journals that address over 30 patient conditions, we have seen great patient outcomes in these studies and look forward to benefiting from the market scale commercialization that this relationship with Adapttech will deliver.”
Adapttech will release new technology in 2022 incorporating licensed IP from Modus Health.
Adapttech is a biomedical company focused on developing technologies that empower healthcare providers to help people with physical limitations to improve their quality of life. In 2021, the company closed a £2 million funding round. The round was supported by existing investors including the MEIF Proof of Concept & Early Stage Fund, Midlands Engine Investment Fund; Bionova Capital, and new investors including ACF Investors, Wealth Club and Wren Capital. www.adapttech.eu